Literature DB >> 6206732

Discovery of a cholecystokinin analogue with partial agonist activity.

J M Howard, M Knight, R T Jensen, J D Gardner.   

Abstract

In dispersed acini from guinea pig pancreas, cholecystokinin-(27-32)-amide [CCK-(27-32)-NH2] did not stimulate amylase secretion and inhibited the stimulation caused by CCK-(26-33). In dispersed acini from mouse or rat pancreas, CCK-(27-32)-NH2 stimulated amylase secretion. The stimulation of amylase secretion caused by a maximally effective concentration of CCK-(27-32)-NH2 was less than that caused by a maximally effective concentration of cholecystokinin-(26-33), and in contrast to the action of cholecystokinin-(26-33) supramaximal concentrations of CCK-(27-32)-NH2 did not cause submaximal stimulation of amylase secretion. Dibutyryl cGMP and proglumide each inhibited the stimulation of amylase secretion caused by CCK-(27-32)-NH2. CCK-(27-32)-NH2 inhibited binding of 125I-labeled CCK to mouse and rat pancreatic acini. These results indicate that, in mouse and rat pancreatic acini, CCK-(27-32)-NH2 is a partial agonist and that this partial agonist activity is produced by occupation of the CCK receptor by CCK-(27-32)-NH2.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206732     DOI: 10.1152/ajpgi.1984.247.3.G261

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990.

Authors:  J P Smith; T E Solomon; S Bagheri; S Kramer
Journal:  Dig Dis Sci       Date:  1990-11       Impact factor: 3.199

Review 2.  CCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders.

Authors:  R T Jensen
Journal:  Yale J Biol Med       Date:  1996 May-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.